Vascular Biogenics Ltd. (NASDAQ:VBLT)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Monday.

Several other equities research analysts have also commented on the stock. Roth Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, August 16th. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 19th. Six investment analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $11.10.

Analyst Recommendations for Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ:VBLT) opened at 4.925 on Monday. Vascular Biogenics has a 52 week low of $2.76 and a 52 week high of $7.58. The firm’s 50-day moving average is $5.05 and its 200 day moving average is $4.34. The stock’s market cap is $116.24 million.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings data on Thursday, November 10th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. On average, equities research analysts expect that Vascular Biogenics will post ($0.60) EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Vascular Biogenics during the second quarter valued at $1,844,000. Turner Investments L.P. bought a new position in Vascular Biogenics during the second quarter worth approximately $1,007,000. First Eagle Investment Management LLC increased its position in Vascular Biogenics by 371.1% in the second quarter. First Eagle Investment Management LLC now owns 923,239 shares of the biopharmaceutical company’s stock worth $4,256,000 after buying an additional 727,273 shares in the last quarter. Franklin Resources Inc. bought a new position in Vascular Biogenics during the second quarter worth approximately $4,191,000. Finally, Menta Capital LLC increased its position in Vascular Biogenics by 4.1% in the second quarter. Menta Capital LLC now owns 33,200 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 1,300 shares in the last quarter. 14.41% of the stock is owned by hedge funds and other institutional investors.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

5 Day Chart for NASDAQ:VBLT

Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.